PCOS: Symptoms, Diagnosis, and What to Ask Your Doctor
Advertisement
Irregular periods, unwanted facial or body hair, acne that outlasts the teenage years, or difficulty conceiving can each have many explanations. One possibility is polycystic ovary syndrome (PCOS), a common hormonal and metabolic condition that affects reproductive-aged women. You may also see a newer name, polyendocrine metabolic ovarian syndrome (PMOS), on NHS pages and in materials linked to the 2023 international evidence-based guideline hosted with the American Society for Reproductive Medicine (ASRM), as well as in ESHRE and NICHD/NIH materials.
PCOS is not a single symptom and is not the same as "having cysts on the ovaries." It is a group of features, typically some combination of ovulatory problems (irregular or absent periods), higher androgen activity (clinical signs and/or blood tests), and polycystic ovarian morphology on ultrasound or, in adults under 2023 international guidance, an AMH blood marker as an alternative, after other causes are excluded. The European Society of Human Reproduction and Embryology (ESHRE) has long recognised that "polycystic" is misleading because there is no true cyst formation; the Endocrine Society and NHS explain that the ovaries often contain many small follicles that look like cysts on a scan. Those follicles are not the same as dangerous tumours or surgical cysts.
How common PCOS is depends on criteria and population. Reported ranges include roughly 6%-10% (JAMA), about 7%-10% of US women of childbearing age (Endocrine Society), around 10%-13% (WHO / 2023 international guideline via ASRM), up to about 13 in 100 US reproductive-age women (ACOG), 2-26 in 100 (RCOG), and 8%-13% (Cochrane lifestyle review background). ESHRE materials mention roughly 170 million women worldwide. Those figures use different criteria and populations. WHO also notes that up to about 70% of people with PCOS worldwide may not know they have it.
There is no cure. Symptoms and longer-term risks can be managed with lifestyle measures, medicines chosen by a clinician, and fertility pathways when needed.
Key Takeaways
- PCOS, also called polyendocrine metabolic ovarian syndrome (PMOS) in newer NHS, ASRM, ESHRE, and NICHD materials, is a hormonal/metabolic condition involving some combination of ovulatory dysfunction, androgen excess, and polycystic ovarian morphology after other causes are excluded; "polycystic" usually means many small follicles, not dangerous tumours, and polycystic ovaries alone do not equal PCOS.
- Adult diagnosis typically uses at least 2 of 3 features after exclusions; the 2023 international guideline (ASRM) allows AMH instead of ultrasound in adults, does not require imaging if irregular cycles and hyperandrogenism are both present, uses FNPO ≥20 (not older ≥12 mixed as one rule), and tightens adolescent criteria (ultrasound/AMH not recommended; NHS ultrasound generally only if over 18).
- There is no cure; management is individualised (lifestyle, clinician-chosen cycle/androgen medicines, and fertility-specialist pathways); pregnancy remains possible and contraception is still needed if not trying to conceive (ACOG), while diabetes and other risk figures vary between organisations (for example RCOG vs NICHD).
What PCOS Is (and Why You May Also See "PMOS")
A hormonal and metabolic condition
WHO describes PCOS as a common hormonal disorder in which higher-than-normal androgens can contribute to irregular periods, abnormal ovulation, infertility, and excess facial or body hair and/or acne. The NHS describes what it now calls PMOS as a hormone condition affecting hair growth, periods, fertility, and mood (previously called PCOS), with no cure, though treatments and lifestyle changes can help. The Endocrine Society defines PCOS as a hormone disorder defined by a group of signs and symptoms; androgen excess is a key feature in a large share of people (the Endocrine Society cites roughly 60%-80%), and insulin resistance may worsen androgen excess. NICHD (NIH) describes a set of symptoms related to hormonal imbalance, usually involving at least two of three classic features after clinical evaluation.
Follicles, not dangerous "cysts"
The word "polycystic" confuses many people. RCOG is clear that polycystic ovaries alone do not equal PCOS. ESHRE welcomes the PMOS name in part because "polycystic" has long been recognised as misleading because there is absence of true cyst formation. Endocrine Society patient materials explain that ultrasound often shows many small follicles that look like cysts; those are not the same as dangerous tumours or fluid-filled sacs that need emergency surgery. Some people with PCOS do not have polycystic-appearing ovaries on imaging (WHO; ACOG notes you can have a diagnosis without fluid-filled sacs), and some people have polycystic ovaries without meeting criteria for the syndrome.
Cause unknown; no cure
The cause is not fully known. Genetics, insulin resistance and environmental factors are thought to play a part. The NHS notes that insulin and testosterone not working properly may play a role, and that the condition may be more likely if a close relative has it or with Asian background. The Endocrine Society notes that PCOS appears inherited and that normal-weight women can have PCOS. ACOG similarly states that not everyone with PCOS is overweight. There is no cure (WHO, NHS, ACOG, RCOG, JAMA); management targets symptoms, fertility goals, and long-term risk reduction.
Common Symptoms: Cycles, Androgen Signs, Metabolic and Mood Clues
Symptoms vary widely
Symptoms range from mild to severe; some people have few or none at times (NHS). Common features include:
- Irregular, infrequent, absent, heavy, or unpredictable periods
- Difficulty conceiving or infertility related to infrequent or absent ovulation
- Hirsutism: excess facial or body hair (ACOG's FAQ says hirsutism affects more than 7 in 10 people with PCOS)
- Scalp hair thinning or female-pattern thinning
- Acne or oily skin, including severe or post-adolescent acne that does not respond to usual treatments
- Weight gain or difficulty losing weight, especially around the waist, which is common but not required for diagnosis (Endocrine Society; ACOG "5 Things")
- Acanthosis nigricans: thickened, dark, velvety skin patches often linked with insulin resistance
- Fatigue
- Depression, anxiety, or other mental-health and quality-of-life impacts
- Poor sleep, sometimes linked to sleep apnea
ACOG's FAQ says obesity affects as many as about 4 in 5 people with PCOS.
Not a self-diagnosis checklist
Symptoms are common and can have many causes (NHS); adolescence overlaps normal puberty (ASRM 2023). They orient a clinical conversation. They do not authorise self-diagnosis.
How Clinicians Diagnose It: the "2 of 3" Features, Exclusions, and Why Teens Are Different
Adult diagnosis: at least two of three after excluding other causes
After other causes are excluded, most current guidance bases adult PCOS/PMOS diagnosis on at least two of three features:
- Clinical and/or biochemical hyperandrogenism (signs such as hirsutism or acne, and/or elevated androgens on blood tests)
- Ovulatory dysfunction (irregular or absent ovulation/periods)
- Polycystic ovarian morphology (PCOM) on ultrasound, and, in the 2023 International Evidence-based Guideline recommendations published with ASRM, AMH can be used instead of ultrasound in adults to define PCOM
WHO, RCOG, ASRM's 2023 recommendations (building on Rotterdam / 2018 international criteria), and NICHD's "usually ≥2 of 3" description align with this adult pattern. If irregular cycles and hyperandrogenism are both present, the 2023 international guideline states that ultrasound or AMH is not required for diagnosis in adults. Polycystic ovaries alone do not equal PCOS (RCOG; WHO notes ovarian cysts are not required and some women with PCOS do not have polycystic ovaries).
Historical approaches can differ
NICHD notes that different diagnostic approaches exist: most require two of the three features; one approach emphasises hyperandrogenism plus ovulatory dysfunction; another requires hyperandrogenism plus either ovulatory dysfunction or PCOM. NICHD also notes that current diagnostic guidelines apply to adults and that there are no separate adolescent diagnostic criteria, with "at risk" reassessment language. ASRM's 2023 recommendations give a more specific adolescent algorithm. Which guideline era a clinician uses matters, and there is no single rule for every age and clinic.
Adolescents: stricter rules
Under the 2023 international guideline (ASRM-hosted recommendations), adolescents generally need both hyperandrogenism and ovulatory dysfunction. Ultrasound and AMH are not recommended for adolescent diagnosis because specificity is poor. The NHS states ultrasound is used only if over 18. Adolescents who do not yet meet criteria may be labelled at "increased risk" and reassessed by about eight years after menarche (ASRM 2023). WHO notes irregular periods can be normal near menarche and in perimenopause.
Advertisement
Excluding mimics
Diagnosis is not a checkbox after imaging. Clinicians exclude mimics such as thyroid disease, high prolactin, non-classical congenital adrenal hyperplasia, primary ovarian insufficiency, Cushing's, neoplastic androgen sources, and related endocrine disorders (Endocrine Society; JAMA; ASRM). Sudden severe or rapidly progressive androgen symptoms warrant prompt specialist review (ASRM), not DIY triage.
Ultrasound, Blood Tests, and When Imaging Is Not Needed
What testing often includes
Pathways commonly include history and examination, blood tests for hormones (including testosterone/androgens) and sometimes markers related to insulin resistance, and, when indicated, ovarian ultrasound (NHS; Endocrine Society; JAMA). Newly diagnosed people may also have additional blood testing for insulin resistance and cardiovascular risk (WHO). Screening for type 2 diabetes and cardiovascular risk factors is a recurring theme (JAMA; ACOG; RCOG).
2023 ultrasound PCOM threshold (adults)
The 2023 international evidence-based guideline recommendations published with ASRM define adult PCOM using follicle number per ovary (FNPO) ≥20 in at least one ovary when image quality is adequate. Fallbacks include ovarian volume ≥10 mL or follicle number per section (FNPS) ≥10 when older technology or image quality is insufficient. The threshold of 20 or more comes from the 2023 international guideline published with ASRM.
AMH: an adult alternative, not a self-test
In adults only, the same 2023 recommendations allow AMH as an alternative to ultrasound to define PCOM. AMH is not recommended for adolescent diagnosis, is not a standalone diagnostic test for PCOS by itself, and clinicians should not routinely do both AMH and ultrasound solely to define PCOM (ASRM 2023). Patients should not order AMH as a home substitute for clinical assessment.
When imaging is not needed
If an adult has both irregular cycles and hyperandrogenism, ultrasound or AMH is not required under the 2023 international guideline. Under 18, NHS materials generally do not use ultrasound for this purpose; ASRM 2023 does not recommend ultrasound/AMH for adolescent diagnosis. Lab numeric cutoffs for testosterone or AMH are assay- and clinician-specific.
Related Health Risks: Diabetes, Fertility, Pregnancy, Endometrial Lining, Heart/Metabolic, Sleep, Mental Health
Metabolic and cardiovascular risk
PCOS/PMOS is linked with higher risk of insulin resistance and type 2 diabetes or prediabetes; overweight or obesity (common but not required); metabolic syndrome; abnormal lipids; hypertension; and cardiovascular risk factors (NHS, RCOG, ACOG, WHO, Endocrine Society, NICHD, JAMA, ASRM).
Risk numbers vary between organisations and by outcome:
- RCOG: about 1 or 2 in 10 people with PCOS develop diabetes at some point; risk is higher with age over 40, family diabetes, prior gestational diabetes, or BMI over 30.
- NICHD: insulin resistance in more than half of women with PCOS; metabolic syndrome in roughly 25%-45%; obesity in about 4 in 5; more than half will have type 2 diabetes or prediabetes before early 40s (NICHD figures).
Those are different outcomes and timeframes. They cannot be combined into one "diabetes risk."
Fertility and pregnancy
WHO and NICHD describe PCOS as a leading cause of anovulation and anovulatory infertility. Pregnancy is still possible (ACOG explicitly warns against the myth that people with PCOS cannot get pregnant). Pregnancy may carry higher risk of gestational diabetes, hypertension, preterm delivery, and pre-eclampsia (WHO; Endocrine Society). Fertility and pregnancy pathways are clinician-directed, not DIY ovulation protocols.
Endometrial lining
Prolonged infrequent periods raise concern for endometrial hyperplasia and endometrial (womb) cancer risk (NHS, RCOG, ACOG, WHO, Endocrine Society, NICHD, JAMA). RCOG highlights endometrial cancer risk if there are fewer than about three periods per year and notes that breast and ovarian cancer risk is not increased in its patient information. Regular shedding of the lining, through natural cycles or clinician-guided hormonal protection, matters for long-term endometrial health.
Sleep, liver, and mental health
PCOS is also linked to obstructive sleep apnea (Endocrine Society materials note it may occur in up to about 50%), fatty liver / metabolic liver disease, snoring or daytime drowsiness (RCOG), and depression, anxiety, eating disorders, and negative body image. Risks are not destiny. Lifestyle measures and monitoring can help reduce risk (RCOG, NHS, ACOG).
When to See a Doctor, and What to Ask
When to seek care
The NHS advises a non-urgent GP visit if you think you might have PMOS/PCOS or if symptoms affect everyday life, work, or relationships. Diagnosis is often delayed (ASRM; WHO's undiagnosed estimate). Persistent cycle problems, androgen signs, weight or insulin concerns, fertility goals, mood changes, sleep problems, or a family history of PCOS or diabetes warrant a clinical conversation rather than prolonged self-diagnosis.
If a care plan feels unsettled after diagnosis or treatment discussion, some people ask for a second opinion.
Advertisement
What to ask
The Endocrine Society's patient library offers a ready list of questions for a healthcare provider, including: Do I have PCOS? What are treatment options and their pros and cons? What about fertility after treatment? What lifestyle changes help? What other related health problems should we watch for? Should I see an endocrinologist?
RCOG encourages shared decision-making ("Ask 3 Questions") and regular health checks once diagnosed. Diabetes testing cadence is often every 1-3 years depending on risk; aiming for a period roughly every 3-4 months as one option for endometrial protection; blood pressure and cholesterol checks; and mental-health referral when needed. ACOG emphasises a personalised plan, metabolic monitoring, and, critically, that you still need contraception if you are not trying to conceive, because pregnancy remains possible.
Management: Lifestyle, Cycle and Androgen Care, Fertility Help
No cure: individualised plans
There is no cure. Management is tailored to symptoms and pregnancy goals (ACOG, NHS, Endocrine Society, WHO, JAMA, NICHD, ASRM). Your clinician chooses medicines and doses.
Lifestyle as a core theme
Healthy eating, physical activity, and weight management when overweight are central. Modest weight loss can help cycles and symptoms for some people (ACOG, RCOG, NICHD). RCOG notes medication alone has not been shown better than lifestyle for long-term health, and discusses a BMI range of about 19-25 as a general healthy-weight guide, not a universal prescription. Cochrane (2019): lifestyle may improve free androgen index, weight, and BMI (low-certainty); glucose and live-birth outcomes were uncertain or unstudied in that review. WHO emphasises lifestyle even without weight loss.
Cycle regulation and androgen symptoms
When pregnancy is not desired, combined hormonal contraception is commonly used to regulate cycles and reduce androgen symptoms, and may decrease endometrial cancer risk (ACOG; also NHS, JAMA, NICHD, WHO). NHS materials also mention progestogen-only pills or an intrauterine system among options for irregular periods. Insulin-sensitising medicines (for example the metformin class) are used in some cases (clinician-directed only); NICHD notes metformin is not FDA-approved specifically for PCOS but may be used. Anti-androgens (such as spironolactone), topical eflornithine, and cosmetic hair removal methods are options for hirsutism, with pregnancy cautions. Anti-androgens and related agents are not appropriate if pregnancy is desired or possible without reliable contraception (JAMA, NICHD, NHS). Acne treatments are clinician-guided. Do not stop prescribed medicines without advice (NICHD).
Fertility help (clinician / fertility-specialist pathways only)
Lifestyle comes first for many people trying to conceive. Specialist options include clomifene/clomiphene, letrozole, sometimes metformin as an adjunct, gonadotropins, ovarian drilling, and IVF (NHS, ACOG, NICHD, Endocrine Society, JAMA, WHO). Cochrane (2022): letrozole appears to improve live birth and clinical pregnancy versus SERMs/clomiphene for ovulation induction with timed intercourse (high-certainty for key comparisons). Which agent a clinic prefers is guideline-era and clinician dependent (NICHD); some agents are used off-label (ASRM).
Discuss fertility goals before starting treatments that prevent pregnancy or that risk fetal harm (NICHD).
Living With PCOS: Monitoring, Contraception Myths, and Follow-Up
Lifelong monitoring, not a one-time label
ACOG describes PCOS as a lifelong condition that needs monitoring. After diagnosis, the advice is ongoing attention to glucose/HbA1c or diabetes screening, blood pressure, lipids, weight and lifestyle, sleep symptoms, mood, and endometrial protection when periods are very infrequent (RCOG, ACOG, WHO, JAMA, NHS). Check-up intervals are individual. Confirm the schedule with your clinician.
Contraception and pregnancy myths
A common myth is that people with PCOS cannot get pregnant or do not need birth control. ACOG is explicit: pregnancy is still possible, and you still need contraception if you are not wishing to conceive. Fertility can feel reduced when ovulation is infrequent, but that is not reliable contraception.
Shared decisions and follow-up
Plans change with age, weight, metabolic status, mental health, and whether you are trying to conceive. Ask about referral to gynaecology, endocrinology, or reproductive endocrinology/infertility (REI) when symptoms, fertility goals, or metabolic complexity need specialist input (Endocrine Society; ACOG).
Conclusion
PCOS, also called PMOS (a newer name), is a hormonal and metabolic condition involving ovulatory dysfunction, androgen excess, and/or polycystic ovarian morphology (or adult AMH under 2023 guidance) after exclusions. Polycystic ovaries alone do not equal PCOS. There is no cure; management is individualised. Pregnancy remains possible. Contraception is still needed if you are not trying to conceive (ACOG).
Medical Disclaimer
Content on MED.COM is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with questions about a medical condition. Never disregard professional medical advice or delay seeking it because of something read on this site. If you think you may have a medical emergency, contact local emergency services immediately.
Sources & References
- 1.Polyendocrine metabolic ovarian syndrome (PMOS)
NHS
- 2.Polycystic Ovary Syndrome
Endocrine Society • Jan 24, 2022
- 3.Hormones and Polycystic Ovary Syndrome: What You Need to Know
Endocrine Society
- 4.Polycystic Ovary Syndrome (PCOS) FAQ121
American College of Obstetricians and Gynecologists (ACOG) • Jan 1, 2022
- 5.5 Things You Need to Know About PCOS
American College of Obstetricians and Gynecologists (ACOG) • Aug 1, 2025
- 6.Polycystic ovary syndrome (PCOS): what it means for your long-term health
Royal College of Obstetricians and Gynaecologists (RCOG) • Feb 1, 2022
- 7.Polycystic ovary syndrome
World Health Organization (WHO) • Jan 22, 2026
- 8.About Polycystic Ovary Syndrome (PCOS)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (National Institutes of Health)
- 9.Polycystic Ovary Syndrome (PCOS) fact sheet hub
Eunice Kennedy Shriver National Institute of Child Health and Human Development (National Institutes of Health)
- 10.Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polyendocrine Metabolic Ovarian Syndrome (2023)
American Society for Reproductive Medicine (ASRM) / 2023 International Evidence-based Guideline • Jan 1, 2023
- 11.The effect of a healthy lifestyle for women with polycystic ovary syndrome
Cochrane • Mar 28, 2019
- 12.Aromatase inhibitors for infertility treatment in women with polycystic ovary syndrome
Cochrane • Sep 27, 2022
- 13.What Is Polycystic Ovary Syndrome? (JAMA Patient Page)
JAMA • Jan 18, 2022
- 14.PCOS Name Change
ESHRE
Focus Areas
Stay informed with the latest medical insights from MED.COM
Advertisement
Related Articles
Gynecology & Women's Health
Endometriosis: Symptoms, Diagnosis, and When to See a Gynecologist
Gynecology & Women's Health
Heavy Periods: Common Causes and When to See a Doctor
Gynecology & Women's Health
Pelvic Organ Prolapse: Symptoms, Causes and When to See a GP
Gynecology & Women's Health
Uterine Fibroids: Symptoms, Diagnosis, and When to See a Doctor
Gynecology & Women's Health
Menopause and Perimenopause: Symptoms, Timeline, and When to See a Doctor
Infectious Diseases
